BUY Sun Pharmaceutical Industries Ltd. — Sudip Bandyopadhyay
bySudip BandyopadhyayHorizon: NA (inferred 1 year)31 Jul 2026via NDTV Profit
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·4 Sept · 2d ago
10 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days
Advisor consensus · same horizon·2 Sept · 4d ago
Sun Pharma participated in a White House ceremony, announcing agreements with the U.S. government to prioritize access to affordable medicines. The company committed to Most Favored Nation (MFN) prici
BSE · Company Update·1 Sept · 6d ago
Sun Pharma and its subsidiaries have won an antitrust litigation in the US related to the Lipitor patent settlement. The US Court of Appeals affirmed a summary judgment in their favor, denying class c
BSE · Company Update·17 Aug · 3w ago
3 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·30 Jul · 1mo ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.